Next Article in Journal
Mass Spectrometry-Based Quantification of the Antigens in Aluminum Hydroxide-Adjuvanted Diphtheria-Tetanus-Acellular-Pertussis Combination Vaccines
Previous Article in Journal
Determinants of COVID-19 Vaccine Uptake and Acceptability in the Horn of Africa: Evidence from Somaliland
Previous Article in Special Issue
Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: “Reopening of Society Is Harder than Lock-Down”—A Qualitative Interview Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 7
10.3390/vaccines10071077
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease

by
Nunzia Labarile
1,
Fabio Castellana
2,
Annamaria Sila
2,
Pasqua Letizia Pesole
3,
Sergio Coletta
3,
Margherita Curlo
4,
Rodolfo Sardone
2,
Gianluigi Giannelli
5,* and
Mauro Mastronardi
4
1
Unit of Gastroenterology, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, Research Hospital, Castellana Grotte, 70013 Bari, Italy
2
Unit of Research Methodology and Data Sciences for Population Health, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, Research Hospital, Castellana Grotte, 70013 Bari, Italy
3
Biobank Core Facilities, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy
4
Inflammatory Bowel Disease Unit, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, Research Hospital, Castellana Grotte, 70013 Bari, Italy
5
Scientific Direction, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, Research Hospital, Castellana Grotte, 70013 Bari, Italy
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(7), 1077; https://doi.org/10.3390/vaccines10071077
Submission received: 19 May 2022 / Revised: 29 June 2022 / Accepted: 30 June 2022 / Published: 4 July 2022
(This article belongs to the Special Issue COVID-19 Vaccines in the Context of Patients with Autoimmune Inflammatory Diseases)
Versions Notes

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected the entire planet. The objectives of our study were to compare responses to the vaccine (Pfizer-Biontech COMIRNATY) in a population of patients with intestinal bowel syndrome undergoing different biological therapies or conventional therapy. The study recruited 390 patients who received the first vaccination dose during the dedicated vaccination campaign for inflammatory bowel disease (IBD) patients. The inclusion criteria were a diagnosis of CD or UC and complete vaccination with the Pfizer–BioNTech COVID-19 (Comirnaty) vaccine. The exclusion criteria were other significant diseases or important therapies under way or contraindications to vaccination according to the European drug surveillance recommendations. Linear rank models were run to assess the association between the different therapies and S1/S2 antibodies at three different times. The models showed that in patients with IBD receiving Vedolizumab a significant increase in mean IgG levels was observed, independently of other therapies and confounding factors (β: 57.45, 95% CI 19.62 to 19.00). This study confirmed the complete antibody response to vaccination against COVID-19 in patients with IBD undergoing biological therapy—particularly Vedolizumab treatment—but also a reduced immune response due to concomitant steroid therapy.
Keywords: vaccination; IBD; biological therapy; SARS-CoV-2 vaccination; IBD; biological therapy; SARS-CoV-2

Share and Cite

MDPI and ACS Style

Labarile, N.; Castellana, F.; Sila, A.; Pesole, P.L.; Coletta, S.; Curlo, M.; Sardone, R.; Giannelli, G.; Mastronardi, M. Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease. Vaccines 2022, 10, 1077. https://doi.org/10.3390/vaccines10071077

AMA Style

Labarile N, Castellana F, Sila A, Pesole PL, Coletta S, Curlo M, Sardone R, Giannelli G, Mastronardi M. Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease. Vaccines. 2022; 10(7):1077. https://doi.org/10.3390/vaccines10071077

Chicago/Turabian Style

Labarile, Nunzia, Fabio Castellana, Annamaria Sila, Pasqua Letizia Pesole, Sergio Coletta, Margherita Curlo, Rodolfo Sardone, Gianluigi Giannelli, and Mauro Mastronardi. 2022. "Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease" Vaccines 10, no. 7: 1077. https://doi.org/10.3390/vaccines10071077

APA Style

Labarile, N., Castellana, F., Sila, A., Pesole, P. L., Coletta, S., Curlo, M., Sardone, R., Giannelli, G., & Mastronardi, M. (2022). Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease. Vaccines, 10(7), 1077. https://doi.org/10.3390/vaccines10071077

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop